Aceto Corporation (ACET): Price and Financial Metrics
ACET Price/Volume Stats
| Current price | $5.71 | 52-week high | $21.87 |
| Prev. close | $5.32 | 52-week low | $4.61 |
| Day low | $5.32 | Volume | 298,600 |
| Day high | $5.81 | Avg. volume | 470,953 |
| 50-day MA | $5.97 | Dividend yield | N/A |
| 200-day MA | $10.88 | Market Cap | 245.29M |
ACET Stock Price Chart Interactive Chart >
ACET POWR Grades
- Value is the dimension where ACET ranks best; there it ranks ahead of 65.44% of US stocks.
- ACET's strongest trending metric is Stability; it's been moving up over the last 178 days.
- ACET's current lowest rank is in the Growth metric (where it is better than 3.73% of US stocks).
ACET Stock Summary
- ACET's price/sales ratio is 11.09; that's higher than the P/S ratio of 90.62% of US stocks.
- Revenue growth over the past 12 months for ADICET BIO INC comes in at 156.83%, a number that bests 95.39% of the US stocks we're tracking.
- The volatility of ADICET BIO INC's share price is greater than that of 90.37% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to ADICET BIO INC are AEVA, SRRK, CCCC, ONCT, and VIR.
- ACET's SEC filings can be seen here. And to visit ADICET BIO INC's official web site, go to www.restorbio.com.
ACET Valuation Summary
- ACET's price/sales ratio is 10.5; this is 118.75% higher than that of the median Healthcare stock.
- ACET's price/sales ratio has moved NA NA over the prior 64 months.
Below are key valuation metrics over time for ACET.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACET | 2023-05-01 | 10.5 | 0.9 | -3.8 | -0.4 |
| ACET | 2023-04-28 | 10.0 | 0.9 | -3.6 | -0.2 |
| ACET | 2023-04-27 | 9.9 | 0.8 | -3.6 | -0.2 |
| ACET | 2023-04-26 | 10.1 | 0.9 | -3.6 | -0.2 |
| ACET | 2023-04-25 | 10.5 | 0.9 | -3.7 | -0.4 |
| ACET | 2023-04-24 | 10.5 | 0.9 | -3.8 | -0.4 |
ACET's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACET has a Quality Grade of D, ranking ahead of 8.53% of graded US stocks.
- ACET's asset turnover comes in at 0.043 -- ranking 330th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ACET's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.043 | 1 | -1.841 |
| 2021-03-31 | 0.027 | 1 | -2.369 |
| 2020-12-31 | 0.157 | 1 | -2.317 |
| 2020-09-30 | 0.031 | 1 | -3.142 |
| 2020-06-30 | 0.000 | NA | -1.790 |
| 2020-03-31 | 0.000 | NA | -1.243 |
ACET Price Target
For more insight on analysts targets of ACET, see our ACET price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $28.29 | Average Broker Recommendation | 1.21 (Strong Buy) |
Aceto Corporation (ACET) Company Bio
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.
Latest ACET News From Around the Web
Below are the latest news stories about ADICET BIO INC that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare ConferenceREDWOOD CITY, Calif. & BOSTON, June 01, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York. |
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON, May 31, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on May 31, 2023. |
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingREDWOOD CITY, Calif. & BOSTON, May 18, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023, |
Adicet Bio to Present at the 2023 JMP Securities Life Sciences ConferenceREDWOOD CITY, Calif. & BOSTON, May 09, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 JMP Securities Life Sciences Conference being held from May 15-16, 2023 in New York. |
Adicet Reports First Quarter 2023 Financial Results and Provides Business UpdatesREDWOOD CITY, Calif. & BOSTON, May 09, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023. |
ACET Price Returns
| 1-mo | -15.16% |
| 3-mo | -20.03% |
| 6-mo | -66.94% |
| 1-year | -55.39% |
| 3-year | -63.42% |
| 5-year | N/A |
| YTD | -36.13% |
| 2022 | -48.89% |
| 2021 | 24.48% |
| 2020 | 34.71% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...